Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Valerio Therapeutics (ALVIO) - Net Assets
Latest net assets as of June 2025: €-8.45 Million EUR
Based on the latest financial reports, Valerio Therapeutics (ALVIO) has net assets worth €-8.45 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€20.44 Million) and total liabilities (€28.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-8.45 Million |
| % of Total Assets | -41.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | -128.46% |
| 10-Year Change | -108.04% |
| Growth Volatility | 352.38 |
Valerio Therapeutics - Net Assets Trend (2005–2024)
This chart illustrates how Valerio Therapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Valerio Therapeutics (2005–2024)
The table below shows the annual net assets of Valerio Therapeutics from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-8.27 Million | -155.83% |
| 2023-12-31 | €14.80 Million | -33.52% |
| 2022-12-31 | €22.27 Million | -32.40% |
| 2021-12-31 | €32.94 Million | +13.45% |
| 2020-12-31 | €29.04 Million | +68.84% |
| 2019-12-31 | €17.20 Million | -62.12% |
| 2018-12-31 | €45.40 Million | -8.97% |
| 2017-12-31 | €49.87 Million | -46.99% |
| 2016-12-31 | €94.09 Million | -8.47% |
| 2015-12-31 | €102.80 Million | -15.72% |
| 2014-12-31 | €121.97 Million | +1539.89% |
| 2013-12-31 | €7.44 Million | -36.66% |
| 2012-12-31 | €11.74 Million | -48.73% |
| 2011-12-31 | €22.90 Million | +21.48% |
| 2010-12-31 | €18.85 Million | +47.73% |
| 2009-12-31 | €12.76 Million | -53.12% |
| 2008-12-31 | €27.22 Million | -41.45% |
| 2007-12-31 | €46.49 Million | +145.02% |
| 2006-12-31 | €18.97 Million | -35.82% |
| 2005-12-31 | €29.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Valerio Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3850928100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €21.61 Million | % |
| Other Components | €15.66 Million | % |
| Total Equity | €-8.93 Million | 100.00% |
Valerio Therapeutics Competitors by Market Cap
The table below lists competitors of Valerio Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northern Superior Resources Inc
OTCQB:NSUPF
|
$53.88 Million |
|
An Phat Holdings JSC
VN:APH
|
$53.89 Million |
|
Ferrum S.A.
BA:FERR
|
$53.90 Million |
|
Nerdy Inc
NYSE:NRDY
|
$53.91 Million |
|
GRIGEO AB EO -29
F:WM8
|
$53.87 Million |
|
Columbus Acquisition Corp Unit
NASDAQ:COLAU
|
$53.86 Million |
|
UEM Edgenta Bhd
KLSE:1368
|
$53.85 Million |
|
Pacific Construction Co Ltd
TW:2506
|
$53.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valerio Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,805,000 to -8,930,000, a change of -23,735,000 (-160.3%).
- Net loss of 23,931,000 reduced equity.
- Share repurchases of 24,000 reduced equity.
- New share issuances of 24,000 increased equity.
- Other comprehensive income increased equity by 32,372,000.
- Other factors decreased equity by 32,176,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.93 Million | -267.98% |
| Share Repurchases | €24.00K | -0.27% |
| Share Issuances | €24.00K | +0.27% |
| Other Comprehensive Income | €32.37 Million | +362.51% |
| Other Changes | €-32.18 Million | -360.31% |
| Total Change | €- | -160.32% |
Book Value vs Market Value Analysis
This analysis compares Valerio Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €2.88 | €0.13 | x |
| 2006-12-31 | €2.10 | €0.13 | x |
| 2007-12-31 | €3.57 | €0.13 | x |
| 2008-12-31 | €2.02 | €0.13 | x |
| 2009-12-31 | €0.95 | €0.13 | x |
| 2010-12-31 | €1.29 | €0.13 | x |
| 2011-12-31 | €1.29 | €0.13 | x |
| 2012-12-31 | €0.66 | €0.13 | x |
| 2013-12-31 | €0.36 | €0.13 | x |
| 2014-12-31 | €2.99 | €0.13 | x |
| 2015-12-31 | €2.52 | €0.13 | x |
| 2016-12-31 | €1.99 | €0.13 | x |
| 2017-12-31 | €0.98 | €0.13 | x |
| 2018-12-31 | €0.85 | €0.13 | x |
| 2019-12-31 | €0.28 | €0.13 | x |
| 2020-12-31 | €0.38 | €0.13 | x |
| 2021-12-31 | €0.37 | €0.13 | x |
| 2022-12-31 | €0.21 | €0.13 | x |
| 2023-12-31 | €0.11 | €0.13 | x |
| 2024-12-31 | €-0.06 | €0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valerio Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1334.69%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-65.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -26.00% | 0.00% | 0.00x | 1.12x | €-10.64 Million |
| 2006 | -69.39% | -2863.06% | 0.02x | 1.20x | €-15.06 Million |
| 2007 | -39.25% | -517.06% | 0.06x | 1.37x | €-22.90 Million |
| 2008 | -78.49% | -261.39% | 0.19x | 1.56x | €-24.09 Million |
| 2009 | -120.54% | -204.12% | 0.35x | 1.67x | €-16.66 Million |
| 2010 | 14.90% | 12.47% | 0.86x | 1.40x | €924.05K |
| 2011 | -63.85% | -452.57% | 0.09x | 1.49x | €-16.91 Million |
| 2012 | -98.34% | -286.68% | 0.18x | 1.88x | €-12.72 Million |
| 2013 | -205.98% | -1044.53% | 0.08x | 2.39x | €-16.06 Million |
| 2014 | -6.31% | -34.87% | 0.15x | 1.25x | €-19.90 Million |
| 2015 | -18.88% | -557.41% | 0.03x | 1.26x | €-29.69 Million |
| 2016 | -24.10% | -512.45% | 0.04x | 1.33x | €-32.08 Million |
| 2017 | -118.44% | -621.47% | 0.12x | 1.57x | €-64.06 Million |
| 2018 | -20.70% | -153.40% | 0.10x | 1.39x | €-13.94 Million |
| 2019 | -196.13% | -786.57% | 0.11x | 2.19x | €-35.45 Million |
| 2020 | 3.75% | 61.32% | 0.04x | 1.60x | €-1.81 Million |
| 2021 | -18.02% | -146.16% | 0.08x | 1.61x | €-9.23 Million |
| 2022 | -87.84% | -1355.65% | 0.03x | 1.93x | €-21.79 Million |
| 2023 | -137.41% | -1130.22% | 0.05x | 2.38x | €-21.82 Million |
| 2024 | 0.00% | -1334.69% | 0.10x | 0.00x | €-23.04 Million |
Industry Comparison
This section compares Valerio Therapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valerio Therapeutics (ALVIO) | €-8.45 Million | -26.00% | N/A | $53.88 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |